

Attorney Docket No.: ACY-33377

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Metcalf et al.

Serial No.: 09/674,368

(entry into U.S. National Stage from

PCT/US99/09486

Filed: April 29, 1999

(PCT filed January 29, 1998)

For: Vaccines Containing Recombinant Pilin

Against Neisseria Gonhorrhoeae or Neisseria

Meningitidis

Group Art Unit: TBD

Examiner: TBD

Atty. Dkt. No.: ACY-33377

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. § 371

Commissioner for Patents
Box PCT
U.S. Patent and Trademark
Office
P.O. Box 2327
Arlington, Va 22202

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ET937267823US addressed to the Commissioner for Patents, Box PCT, U. S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

12/11/01

Date

Anand P. Iyer, Ph.D.

Sir:

In a "Notification of Missing Requirements under 35 U.S.C. §371", (the "Notification") mailed June 11, 2001, the Examiner stated that the Applicants had not submitted the required sequence listing pursuant to 37 C. F. R. §1.821 - §1.825. The Examiner also set a two-month time-period to comply with the Notification from the mailing date.

In response, Applicants submit herewith a substitute computer readable form of the

Sequence Listing as required under 37 C.F.R.§1.821-§1.825, along with a copy of the

Notification. Applicants also submit that the sequence information provided in the

Specification is the same as the sequence listing of the enclosed substitute computer readable

form of the sequence listing. The Applicants, in accordance with 37 C.F.R. §1.821(g), also

attest that no new matter is included with this submission.

In addition, the Applicants have also submitted herewith a "Petition for Extension of

Time", for four months extension with the authorization to charge the extension fees to

Applicants' Deposit Account No. 01-1300. If any additional fee is required, the Patent Office

is authorized to charge the Applicants' Deposit Account No. 01-1300.

Respectfully submitted,

Oln M. Horch

Alan M. Gordon

Reg. No. 30,637

Attorney for Applicants

American Home Products Corp. Five Giralda Farms Madison, NJ 07940 (845) 602-2189

Date:

12/11/01



UNITED STATES PATENT AND TRADEMARK OFFICE Patent Law Department Pearl River, NY

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231 www.yspto.gov

| | ٠. | | | Washington, D.C. |
|----------------------------------|--|-----------------|--------------|------------------|
| U.S APPLICATION NO. | FIRST NAMED APPLICANT | | | TTY. DOCKET NO. |
| 09/674368 | METCALF | T | | 33377-00 |
| | | INTE | RNATIONAL AF | PLICATION NO. |
| ALAN M GORDÓN | | | PCT/US9 | 9/09486 |
| PATENT LAW DEPARTMENT | 2B | র া ড় | | |
| AMERICAN HOME PRODUCT | 'S CORPORATION | I.A. FILIN | G DATE | PRIORITY DATE |
| ONE CAMPUS DRIVE | | 29 AF | PR 99 | 4 |
| PARSIPPANY, NJ 07054 | 8-1101 | | 1.1 | JUN 2001 |
| | (ad) w/ 14/0/ | DATI | MAILED: | E GÓTA TOÓL |
| NOTIFICATION OF MI | SSING REQUIREMENTS UNDER | 35 U.S.C | . 371 IN | THE UNITED |
| | S DESIGNATED/ELECTED OFFI | | | - |
| 1. The following items have been | submitted by the applicant or the IB to the Ur | iited States Pa | tent and Tr | ademark |
| Office as a Designated | Office (37 CFR 1.494) an Elected Office | e (37 CFR 1.4 | 195): | |
| - ILO Deste Mediese LE | Indication of Small En | rim. Crapus | | |

| STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) |
|--|
| • |
| L. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office asa Designated Office (37 CFR 1.494)a n Elected Office (37 CFR 1.495): |
| U.S. Basic National Fee. Indication of Small Entity Status. |
| Copy of the international application. Translation of the international application into English. |
| (x) Copy of the international application. (x) Translation of the international application of English. (x) Translation of Article 19 amendments into English. |
| Comment Amenda 10 amend to page |
| |
| Priority Document. |
| The International Preliminary Examination Report in English and its Annexes, if any. |
| Translation of Annexes to the International Preliminary Examination Report into English. |
| 2. Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or |
| the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed |
| prior to 20 or 30 months from the priority date to avoid abandonment. |
| U.S. Basic National Fee. Copy of the international application. |
| |
| 3. The following items MUST be furnished within the period set forth below in order to complete the requirements for |
| acceptance under 35 U.S.C. 371: [] a. Translation of the application into English. A processing fee will be required if submitted |
| later than the appropriate 20 or 30 months from the priority date. |
| The current translation is defective for the reasons indicated on the attached Notice of Defective |
| Translation. |
| b. Processing fee for providing the translation of the application and/or the Annexes later than the |
| appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)). |
| c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying |
| the application (preferably by the International application number and international filing date). A |
| surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority |
| date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons |
| indicated on the attached PCT/DO/EO/917. |
| d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the |
| priority date (37 CFR 1.492(e)). |
| 4. Additional claim fees of \$ as a \[\] large entity \[\] small entity, including any required multiple dependent |
| claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are |
| due (37 CFR 1.492(g)). See attached PTO-875. |
| 5. pm Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached |
| |
| PCT/DO/EO/920. |
| ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) |
| MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM |
| THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT. |
| RESTORD WILL RESULT IN ABANDONALENT. |
| The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR |
| 1.136(a). |
| C. 151. 20. 4 |
| 6: If box 3a or 3c is checked, a translation of the Annexes MUST be submitted no later than the time period set above or the |
| Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date. 7. The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) |
| or 30 (37 CFR 1.495(d)) months from the priority date. |
| To be the first of |
| Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the |
| address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5) |
| A come of this notice MIST he returned with this record |
| Enclosed: PCTIDOIEO1917 ENCORED STREET Franklation RECEIVI |
| Company of the second of the s |

| Enclosed: PCT/DO/EO/917 Enclosed: PCT/DO/EO/917 | eturned with this response. | RECEIVED |
|---|-----------------------------|---------------|
| ☐ PTO-875 | Deborah D. Williams | JUN 1 3 2001 |
| FORM PCT/DO/EO/905 (March: 2001) | rephone: 703-305-3744 | ANNETTE CROME |
| | / ARAP AL | ALL ADI EA |

BEST AVAILABLE COPY


| FORTU & LARRY | | | | | Washington, D.C. | | | | |
|--|---|--|--|---|---|--|--|--|--|
| U.S. APPLICATION NO. | | F | IRST NAMED APPLICANT | | ATTY, DOCKET NO. | | | | |
| 09/6743 | 368 | | IETCALF | Т | 33377-00 | | | | |
| | | | | INTERNA | TERNATIONAL APPLICATION NO. | | | | |
| ALAN M GORDON | | 20 | į | PC | T/US99/09486 | | | | |
| PATENT LAW DEF | | | | 1. 50000 | | | | | |
| ONE CAMPUS DR | IVE | | | I.A. FIUNG D | 1 | | | | |
| PARSIPPANY, NJ | 07054 | | | 29 APR 9 | 3 9 | | | | |
| l | | | | DATE MA | ILED: 1 1 JUN 2001 | | | | |
| NOTIFICATIO CONTAIN | ON TO CO | LEOTIDE SEQU | EQUIREMENTS ENCE AND/OR CLOSURES | S FOR PATEN | NT APPLICATIONS | | | | |
| America. The iter deficiency noted by The nucleotide and | ms indicated below and a d/or amino | ers under 35 U.S.C d below, however, void abandonment | . 371 to enter the are missing. This set forth in the losure contained | ne period withing accompanying in this applical | tion does not comply | | | | |
| reason(s): | | • | | | -, | | | | |
| | | ils to comply with | | | | | | | |
| This ap | plication d | oes not contain, a | Sequence Listin | g" as a separat | e part of the | | | | |
| disclos | ure on pape | er copy or compac | t disc, as require | d by 37 CFR 1 | .821(c). | | | | |
| A copy | of the "Se | quence Listing" in | computer readah | ole format has r | not been submitted as | | | | |
| require | d by 37 CF | R 1.821(e). | | | | | | | |
| A copy | of the "Se | quence Listing" in | computer readab | ole form has be | en submitted. The | | | | |
| content | of the com | puter readable for | n. however, doe | s not comply w | ith the requirements of | | | | |
| 37 CFR Sequen | R 1.822 and ce Listing." | or 1.832, as indic | ated on the attack | hed marked-up | copy of the "Raw | | | | |
| | | | | | has been found to be | | | | |
| substitu | ute compute | nreadable as indica er readable form m compact disc of the | ust be submitted | as required by | tte Problem Report. A 37 CFR 1.825(d). | | | | |
| compu | | e form of the "Sequ | | | | | | | |
| Other: | | · · · · · · · · · · · · · · · · · · · | | _ | · . | | | | |
| | | · · · · · · · · · · · · · · · · · · · | | | | | | | |
| | | | • | | | | | | |
| APPLICANT MU | ST PROVI | DE: | | | | | | | |
| | | itute computer read | lable form (CRF |) of the "Seque | nce Listing " | | | | |
| | | | | | Listing," as well as an | | | | |
| | | | | the Sequence | Listing, as well as an | | | | |
| A state | ment that the | ing its entry into the properties of the propert | e specification. Saper or compact | disc and the co | omputer readable form | | | | |
| are the | same and, | where applicable, 1.821(g), 1.825(b | include no new n | | | | | | |
| FOR QUESTIONS CALL: | S REGARE | ING COMPLIAN | CE WITH THE | SE REQUIREN | MENTS, PLEASE | | | | |
| | -4216, for | Rules interpretation | n. | | | | | | |
| (703) 308 | -4212, for | CRF submission h | elp. | | | | | | |
| | | Patentin software | | | - | | | | |
| • | | | | | | | | | |
| | | | | | · 4.1 | | | | |

Deborah D. Williams

FORM PCT/DO/EO/920 (March 2001)

BEST AVAILABLE SOPY

RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

Dirlog

Source:

Date Processed by STIC:

Commence of the control of the contr

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO).

Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:

http://www.uspto.gov/web/offices/pac/checker

Raw Sequence Listing Error Summary

| | | 00/12/12/18 |
|----------|---|--|
| i | ERROR DETECTED | SUGGESTED CORRECTION SERIAL NUMBER: 09/674,368 |
| ATTA | | LEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE The number/text at the end of each line "wrapped" down to the next line. |
| 1 | _ Wrapped Nucleics | The number text at the end of each line whapped down to the flex line. This may occur if your file was retrieved in a word processor after creating it. |
| | | Please adjust your right margin to .3, as this will prevent "wrapping". |
| 2 | _ Wrapped Aminos | The amino acid number/text at the end of each line "wrapped" down to the next line. |
| | • · · · · · · · · · · · · · · · · · · · | This may occur if your file was retrieved in a word processor after creating it. |
| | | Please adjust your right margin to .3, as this will prevent "wrapping". |
| 3 | Incorrect Line Length | The rules require that a line not exceed 72 characters in length. This includes spaces. |
| 4 | Misaligned Amino Acid | The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs |
| 1 | Numbering | between the numbering. It is recommended to delete any tabs and use spacing between the numbers. |
| 51 | Non-ASCII | This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. |
| <u> </u> | , Non-Ason | Please ensure your subsequent submission is saved in ASCII text so that it can be processed. |
| 6 | Variable Length | Sequence(s) contain n's or Xaa's which represented more than one residue. |
| | - | As per the rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and |
| | | indicate in the (ix) feature section that some may be missing. |
| 7 | Patentin ver. 2.0 "bug" | A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid |
| | • | sequence(s) Normally, Patentin would automatically generate this section from the |
| | | previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223> |
| | | sections for Artificial or Unknown sequences. |
| | | |
| 8 | Skipped Sequences | Sequence(s) missing. If intentional, please use the following format for each skipped sequence: |
| | (OLD RULES) | (2) INFORMATION FOR SEQ ID NO:X: (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS") |
| | | (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: |
| | | This sequence is intentionally skipped |
| | | Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s). |
| 9 | Skipped Sequences | Sequence(s) missing. If intentional, please use the following format for each skipped sequence. |
| | (NEW RULES) | <210> sequence id number |
| | | \$400> sequence id number |
| | | 000 |
| 0 | Use of n's or Xaa's | Use of n's and/or Xaa's have been detected in the Sequence Listing. |
| | (NEW RULES) | Use of <220> to <223> is MANDATORY if n's or Xaa's are present. |
| | | In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents. |
| 1 | Use of <213>Organism | Sequence(s) are missing this mandatory field or its response. |
| | (NEW RULES) | |
| • | Lles et «220» Feature | Sequence(s) are missing the <220>Feature and associated headings. |
| | Use of <220>Feature (NEW RULES) | Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown" |
| | | Please explain source of genetic material in <220> to <223> section. |
| / | • | (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Ru |
| . 1/ | 0.4 .44 0.00 | Please do not use "Copy to Disk" function of Patentin version 2.0. This causes a corrupted |
| 1 T/ | Patentin ver. 2.0 "bug" | Please do not use. Copy to bisk function of Paternia Version 2.5. This educate a complete version 2.5. This educate a complete version 2.5. The Educate version 2.5. This educ |
| | | the, resulting in missing manufactory manufactory manufactory manufactory file to financy disk |

PC!

TIME: 11:37:48 PATENT APPLICATION: US/09/674,368 Does Not Comply Corrected Diskette Needer Input Set : A:\PTO.txt Output Set: N:\CRF3\03072001\1674368.raw 5 <110> APPLICANT: American Cyanamid Company 7 <120> TITLE OF INVENTION: Vaccines Containing Recombinant Pilin Against Neisseria Gonorrhoeae or Neisseria Meningitidis sel dem 5 on End 11 <130> FILE REFERENCE: 33377-00/PCT 13 <140> CURRENT APPLICATION NUMBER: US/09/674,368
14 <141> CURRENT FILING DATE: 2000-10-27 Summary Sheet 16 <160> NUMBER OF SEQ ID NOS: 24 18 <170> SOFTWARE: PatentIn Ver. 2.0 ERRORED SEQUENCES 299 <210> SEQ ID NO: 13 move up - format enow (see item I on Even Summany Sheet) 300 <211> LENGTH: 31 301 <212> TYPE: DNA 303 <213> ORGANISM: Neisseria Meningitidis Class I 305 <400> SEQUENCE: 13 E--> 306 ccggcgcgtc tctcacggcg aatggcccgg c 307 396 <210> SEQ ID NO: 24 397 <211> LENGTH: 22 398 <212> TYPE: PRT 399 <213> ORGANISM: Neisseria gonorrhoeae 404 <400> SEQUENCE: 24 405 Glu Ala Ile Leu Leu Ala Glu Gly Gln Lys Ser Ala Val Thr Glu Tyr 10 406 1 408 Tyr Leu Asn His Gly Lys 20 410 E--> 441/1 E--> 443/8 delete at end I file ACY-33377-00 445 see follning pages for more error

RAW SEQUENCE LISTING

DATE: 03/07/2001

DATE: 03/07/2001 VERIFICATION SUMMARY TIME: 11:37:50 PATENT APPLICATION: US/09/674,368

Input Set : A:\PTO.txt

Output Set: N:\CRF3\03072001\I674368.raw

L:13 M:270 C: Current Application Number differs, Replaced Application Number $L:14\ M:271\ C:$ Current Filing Date differs, Replaced Current Filing Date L:60 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1 L:64 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1 L:68 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1 L:72 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1 $\text{L:76}\ \text{M:336}\ \text{W:}$ Invalid Amino Acid Number in Coding Region, SEQ ID:1 L:80 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1 L:87 M:258 W: Mandatory Feature missing, <220> FEATURE: L:87 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION: L:194 M:258 W: Mandatory Feature missing, <220> FEATURE: L:194 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:

L:306 M:254 E: No. of Bases conflict, LENGTH:Input:0 Counted:31 SEQ:13

L:441 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:24

M:332 Repeated in SeqNo=24

4

RAW SEQUENCE LISTING DATE: 03/14/2001 PATENT APPLICATION: US/09/674,368 TIME: 12:10:34

Input Set : A:\Pto.amc

Output Set: N:\CRF3\03142001\1674368.raw

| | 142 | 1 | | | | 5 | | | | | 10 | | | | | . 15 | | 0.6 | | | | |
|-------|-----|------|-----|----------|--------|------------|---------|------|------------------|-------|------|-------------|-----------|------|-----|-------|------|------------|-----|---------|--------------|----------|
| | 144 | atc | gcc | atc | gtc | ggt | atc | ttg | gca | gcc | gtc | gcc | ctg | ccc | gca | tac | caa | 96 | | | | |
| | 145 | Ile | Ala | Ile | | | Ile | Leu | Ala | | | Ala | Leu | Pro | | Tyr | GIn | | | | | |
| | 146 | | | | 20 | | | | | 25 | | | | | 30 | | | 244 | | | | |
| | 148 | gac | tac | acc | gcg | cgc | gcc | caa | atg | tcc | gaa | gcc | ctg | act | ttg | gca | gaa | 144 | | | | |
| | | Asp | Tyr | | Ala | Arg | Ala | GIn | | Ser | Glu | Ala | Leu | Thr | Leu | Ala | GIU | | • | | | |
| | 150 | | | 35 | | | | | 40 | | | | | 45 | ~~~ | 202 | | 192 | | | | |
| | 152 | ggt | caa | aaa - | tcc | gca | gtg | atc | gag | tat | Tat | tcc | gac | dac | 01 | The | Dho | 134 | | | | |
| | | Gly | | Lys | Ser | Ala | val | | GIU | TYI | TŸI | Ser | ASP 60 | ASII | GIY | 1 111 | FILE | | | | | |
| | 154 | | 50 | | | | + | 55 | ~~+ | a++ | ant. | acc | | 220 | gag | att | 222 | 240 | | | | |
| | 120 | ccg | aac | agc | aat | act mh~ | 505 | y Ca | 614 | Tla | λla | gcc Ala | Ser | Acn | Glu | Tle | Lvs | 2.0 | | | | |
| | | | | ser | ASII | ıiıı | 70 | MIG | GLY | 116 | Ata | 75 | Jei | K311 | 014 | 110 | 80 | • | | | | |
| | | 65 | | + > + | ata | ac 2 | | at t | aan | att | ga a | ggt | aat | acc | tct | att | | 288 | | | | |
| | 100 | C111 | Tue | Tur | Val | Δla | Ser | Val | Lvs | Val | Glu | Gly | Asn | Ala | Ser | Val | Ala | | | | | |
| | 162 | GIY | пÃЭ | ı yı | ¥ CL I | 85 | 001 | , | D _I U | , | 90 | 4 -1 | | • | | 95 | | | | | | |
| | | tot | att | acc | act | | atq | aac | tet | agt | | gtg | aat | aaq | qac | atc | aaa | 336 | | | | |
| | 165 | Ser | Tle | Thr | Ala | Thr | Met | Asn | Ser | Ser | Asn | Val | Asn | Lys | Asp | Ile | Lys | | | | | |
| | 166 | 001 | 110 | | 100 | | | | | 105 | | | | - | 110 | | _ | | | | | |
| | | aat | aaa | acc | | qta | ctc | gtc | qqc | aaa | caa | aac | tcc | ggt | tcg | gta | aaa | 384 | | | | |
| | 170 | Gly | Lys | Thr | Leu | Val | Leu | Val | Gly | Lys | Gln | Asn | Ser | Gly | Ser | Val | Lys | | | | | |
| | 171 | _ | | 115 | | | | | 120 | | | | | 125 | | | | | | | | |
| | 173 | tgg | ttc | tgc | gga | cag | ccg | gtt | acg | cgc | gac | aac | gcc | gac | aac | gac | gac | 432 | | | | |
| | 174 | Trp | Phe | Cys | Gly | Gln | Pro | Val | Thr | Arg | Asp | Asn | Ala | Asp | Asn | Asp | Asp | | | | | |
| | 175 | | 130 | | | | | 135 | | | | | 140 | | | | | | | | | |
| | 177 | gtc | aaa | gac | gcc | ggc | aac | aac | ggc | atc | gaa | acc | aag | cac | ctg | ccg | tca | 480 | | | | |
| | 178 | Val | Lys | Asp | Ala | Gly | | | Gly | Ile | Glu | Thr | Lys | His | Leu | Pro | Ser | | | | | |
| | | 145 | | | | | 150 | | | | | 155 | | | | | 160 | 510 | | | | |
| | 181 | acc | tgc | cgc | gat | acg | tca | tct | gat | gcc | aaa | | | | | | | 510 | | | | |
| | | Thr | Cys | Arg | Asp | | Ser | Ser | Asp | Ala | | | | | | | • | | | | | |
| | 183 | | | | | 165 | | | | | 170 | | | | | | | | | | | |
| | | <210 | | | | | | | | | | | | | | | | | | | | |
| | | <211 | | | | <i>,</i> 0 | | | | | | | | | | | | | | • | , | \sim |
| | | <212 | | | | Arti | fici | ו ב | Seque | ance | | | , | | _ | | | . ^ | -00 | Hos | . / | 3 Let |
| rar S | | | | | | ALU | LIICI | Lai | eque | Siice | | | | -) . | Ω. | en | 1 D | M - | sec | | ~ / . | ر |
| W> | | | | | | יבאמר | י ד האי | | | _ | | | / | , , | | | • | | | 0 | | |
| W> | | <400 | / | | | | LON | | | | | | | | | | | | dh | 200 | L | |
| | 191 | Met | Glu | Δla | Tle | Gln | Lvs | Glv | Phe | Thr | Leu | Ile | Glu | Leu | Met | Ile | Val | | 1 | | | 117 |
| | 193 | | 014 | | 110 | 5 | -10 | 0-1 | | | 10 | | | | | 15 | | | Au | 4.4 | 1 | Les |
| | | | Ala | Ile | Val | Glv | Ile | Leu | Ala | Ala | Val | Ala | Leu | Pro | Ala | Tyr | Gln | | Bus | <i></i> | 7 | - / |
| | 196 | | | | 20 | | | | | 25 | | | | | 30 | _ | | | | | | |
| | | Asp | Tyr | Thr | Ala | Arg | Ala | Gln | Met | Ser | Glu | Ala | Leu | Thr | Leu | Ala | Glu | | | | | |
| | 199 | • | • | 35 | | - | | | 40 | | | | | 45 | | | | | | | | |
| | 201 | Gly | Gln | Lys | Ser | Ala | Val | Ile | Glu | Tyr | Tyr | Ser | Asp | Asn | Gly | Thr | Phe | | | | | |
| | 202 | _ | 50 | | | | | 55 | | | | | 60 | | | | | | | | | |
| | 204 | Pro | Asn | Ser | Asn | Thr | Ser | Ala | Gly | Ile | Ala | Ala | Ser | Asn | Glu | Ile | | | | | | |
| | 205 | 65 | | | | | 70 | | | | | 75 | | | _ | | 80 | | | - | | |
| | 207 | Gly | Lys | Tyr | Val | Ala | Ser | Val | Lys | Val | Glu | Gly | Asn | Ala | Ser | \al | Ala | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | |

DATE: 03/14/2001

PATENT APPLICATION: US/09/674,368 TIME: 12:10:34 Input Set : A:\Pto.amc Output Set: N:\CRF3\03142001\1674368.raw 71 gcc aag acc gcc gac aac atc aac acc aag cac ctg ccg tca acc tgc 480 72 Ala Lys Thr Ala Asp Asn Ile Asn Thr Lys His Leu Pro Ser Thr Cys 150 155 75 cgc gac gca agt gat gcc agc taa 504 76 Arg Asp Ala Ser Asp Ala Ser > 77 79 <210> SEQ ID NO: 2 80 <211> LENGTH: 167 whet I le Val

So Ala Tyr Gln

30

Su Leu Ala Glu

5

5 Gly Glu Trp

Men 13

Men 14

Men 15

Men 15 81 <212> TYPE: PRT 82 ORGANISM: Artificial Sequence W--> 84 <220> FEATURE: 84 (223) OTHER INFORMATION: 84 (400) SEQUENCE: 2 W--> 84 85 Met Asp Thr Leu Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val 86 1 10 88 Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln 25 92 Asp Tyr Thr Ala Arg Ala Gln Val Ser Glu Ala Ile Leu Leu Ala Glu 35 4.0 96 Gly Gln Lys Ser Ala Val Thr Glu Tyr Tyr Leu Asn His Gly Glu Trp 50 55 60 100 Pro Gly Asn Asn Thr Ser Ala Gly Val Ala Ser Ser Ser Thr Ile Lys 101 65 104 Gly Lys Tyr Val Lys Glu Val Thr Val Ala Asn Gly Val Ile Thr Ala 108 Thr Met Leu Ser Ser Gly Val Asn Lys Glu Ile Gln Gly Lys Lys Leu 100 105 112 Ser Leu Trp Ala Lys Arg Gln Asp Gly Ser Val Lys Trp Phe Cys Gly 115 120 115 Gln Pro Val Thr Arg Thr Asp Ala Lys Ala Asp Thr Val Ala Ala Ala 135 140 118 Ala Lys Thr Ala Asp Asn Ile Asn Thr Lys His Leu Pro Ser Thr Cys 119 145 150 155 121 Arg Asp Ala Ser Asp Ala Ser 122 165 125 <210> SEQ ID NO: 3 126 <211> LENGTH: 510 127 <212> TYPE: DNA 128 <213> ORGANISM: Artificial Sequence 130 <220> FEATURE: 131 <223> OTHER INFORMATION: Description of Artificial Sequence: Chimeric of Neisseria Meningitidis Class II and Neisseria 133 Gonorrhoeae 135 <220> FEATURE: 136 <221> NAME/KEY: CDS 137 <222> LOCATION: (1)..(510) 139 <400> SEQUENCE: 3 140 aty gaa gca atc caa aaa ggt ttc acc ctg atc gag ctg atg atc ytc 141 Met Glu Ala Ile Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val

RAW SEQUENCE LISTING

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

| C |
|---|
| ☐ BLACK BORDERS |
| \square image cut off at top, bottom or sides |
| ☐ FADED TEXT OR DRAWING |
| ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING |
| ☐ SKEWED/SLANTED IMAGES |
| ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS |
| ☐ GRAY SCALE DOCUMENTS |
| ☐ LINES OR MARKS ON ORIGINAL DOCUMENT |
| REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY |
| · |

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER: _____

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.